Why Regeneron Pharmaceuticals, Inc. (REGN) stock moved
No significant move on Nov 19, 2026 (−2.3%, close-to-close). Latest notable session: Nov 11, 2026.
Why Regeneron Pharmaceuticals, Inc. (REGN) rose 4.7% on November 11, 2026
Regeneron Pharmaceuticals, Inc. (REGN) rose 4.7% on November 11, 2026, closing at $959.41 versus $916.06 the prior session (close-to-close, from daily closes). After advancing its CIDEB siRNA experimental therapy targeting metabolic dysfunction-associated steatohepatitis (MASH) to late-stage trials, with Phase I/II data showing a single dose reduced liver fat by up to 80%. The move was also supported by recent analyst price-target increases from Cantor Fitzgerald (to $980) and Truist Securities (to $982), as well as investor focus on the upcoming Eylea HD '036 formulation patent defense at the Patent Trial and Appeal Board. Source: FMP price data; BestStocks detection.
Regeneron Pharmaceuticals, Inc. (REGN) moved +6.01% from $904.99 to $959.41 on 2026-11-11 after advancing its CIDEB siRNA experimental therapy targeting metabolic dysfunction-associated steatohepatitis (MASH) to late-stage trials, with Phase I/II data showing a single dose reduced liver fat by up to 80%. The move was also supported by recent analyst price-target increases from Cantor Fitzgerald (to $980) and Truist Securities (to $982), as well as investor focus on the upcoming Eylea HD '036 formulation patent defense at the Patent Trial and Appeal Board.
What to watch next: Regeneron is scheduled to report earnings on 2027-01-28 (consensus EPS estimate $25.39).
Earlier sessions that moved REGN
- −3.0%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
- −4.4%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
- +3.6%Following upbeat Q3 results that prompted multiple analysts to raise their forecasts, according to Benzinga.
- +13.3%Regeneron reported third-quarter 2026 earnings and revenues that beat analyst estimates (Globe Newswire, Zacks), driving a sharp rally of +11.91% to $916.31. Read the October 30, 2026 analysis →
- +3.3%We checked news, earnings, analyst updates, filings, and corporate actions — no company-specific catalyst was found.
- +3.4%The move followed reports that Dupixent exceeded growth expectations in first-half 2026 results.
- −3.1%Regeneron and Sanofi announced an expansion of their alliance valued at up to $8 billion to develop next-generation, long-acting immunology antibodies alongside their existing DUPIXENT collaboration, according to Globe Newswire and the Wall Street Journal.
- −4.5%Why Regeneron Rival Kodiak Sciences Just Skyrocketed 90%-Plus: Kodiak Sciences stock skyrocketed Monday on a double win for its potential rivals to Regeneron Pharmaceuticals' blockbuster eye drug, Eylea.
- +3.4%Following FDA approval of Pasatru (garetosmab), a first-in-class treatment for fibrodysplasia ossificans progressiva (FOP), per Yahoo Finance.
Regeneron Pharmaceuticals, Inc. (REGN) shares rose 0.0% to $922.65 as of November 20, 2026, a slight gain from the prior close of $922.40. BestStocks flagged the session as a major change for REGN. The move is tied to company news. Below, we break down what changed for REGN, why it matters for investors, how the stock reacted, and the catalysts on the calendar.
Company News
Regeneron presents pivotal trial data for Ordspono in relapsed/refractory marginal zone lymphoma at ASH conference. Positive pivotal data could support FDA approval and expand Ordspono's addressable market across lymphoma indications.
What it means for Regeneron Pharmaceuticals, Inc. investors
For Regeneron Pharmaceuticals, Inc. investors, the recent signals are mixed, leaving the near-term picture neutral / mixed. On the constructive side: Material positive event; Positive 0.0% session move. Weighing against that: Regeneron and Sanofi announced an expansion of their alliance valued at up to $8 billion to develop next-generation, long-acting immunology antibodies alongside their existing DUPIXENT collaboration, according to Globe Newswire and the Wall Street Journal; Regeneron Pharmaceuticals, Inc. moved -3.37% intraday from $788.04 to $761.46. Wall Street's consensus price target sits at $937.29, implying +1.6% upside from $922.65. Over the past 90 days analysts logged 2 upgrades and 0 downgrades. BestStocks rates the overall signal quality weak (30/100). With earnings roughly 69 days out, the next report is the most likely near-term test of the move.
REGN price reaction
REGN last traded at $922.65, up $0.25 (+0.03%) from the previous close of $922.40. The session traded on 0.5× average volume (below avg), so participation was unremarkable.
Bullish and bearish analyst opinions on Regeneron Pharmaceuticals, Inc. (REGN)
The consensus analyst price target on Regeneron Pharmaceuticals, Inc. (REGN) is $937.29, 1.6% above the recent $922.65. Over the past 90 days analysts logged 2 upgrades, 24 maintains, and 0 downgrades. Here is how the bullish and bearish cases on REGN line up.
The bullish case
- Wall Street's consensus price target of $937.29 implies +1.6% upside from $922.65.
- The Street's most bullish target is $1,100.00 (+19.2%).
- 2 analyst upgrades in the past 90 days, most recently UBS to Buy (2026-10-15).
- Material positive event.
- Positive 0.0% session move.
The bearish case
- The most bearish analyst target is $756.00 (-18.1%).
- Regeneron and Sanofi announced an expansion of their alliance valued at up to $8 billion to develop next-generation, long-acting immunology antibodies alongside their existing DUPIXENT collaboration, according to Globe Newswire and the Wall Street Journal.
- Regeneron Pharmaceuticals, Inc. moved -3.37% intraday from $788.04 to $761.46.
Weighing both sides, BestStocks' composite read of recent signals is roughly balanced, as the bull-versus-bear meter above shows. This is an educational summary of the bull and bear case, not investment advice.
Analyst price targets and ratings are FMP consensus figures as of Nov 20, 2026; other aggregators may differ. High and low targets show the range of estimates, not forecasts.
Previous notable changes for REGN
In-depth REGN event analyses
Frequently asked questions about REGN
Why did Regeneron Pharmaceuticals, Inc. (REGN) stock move?
Regeneron Pharmaceuticals, Inc. (REGN) rose 4.7% on November 11, 2026, closing at $959.41 versus $916.06 the prior session (close-to-close, from daily closes). After advancing its CIDEB siRNA experimental therapy targeting metabolic dysfunction-associated steatohepatitis (MASH) to late-stage trials, with Phase I/II data showing a single dose reduced liver fat by up to 80%. The move was also supported by recent analyst price-target increases from Cantor Fitzgerald (to $980) and Truist Securities (to $982), as well as investor focus on the upcoming Eylea HD '036 formulation patent defense at the Patent Trial and Appeal Board. Source: FMP price data; BestStocks detection.
How much did REGN stock rise?
REGN gained 0.03% ($0.25) versus the prior close of $922.40, last trading at $922.65 on 0.5× average volume.
When is Regeneron Pharmaceuticals, Inc.'s next earnings date?
REGN's next earnings report is estimated for 2027-01-28 — about 69 days away.
What is the analyst price target for REGN?
The consensus analyst price target for REGN is $937.29, about 1.6% above the current $922.65. Over the past 90 days, analysts recorded 2 upgrades, 24 maintains, and 0 downgrades.
How BestStocks tracks REGN
This page is generated automatically by BestStocks' change-detection system after company news was detected and verified against independent data sources. It draws on 20 tracked change events for REGN, cross-checked against the data sources listed below. Price, volume, and market-capitalization figures are the live intraday quote as of November 20, 2026 and refresh as new information is detected; for companies with multiple share classes, market-cap figures can differ by data source. Analyst price targets and ratings are FMP consensus. This is an educational summary of what changed and why — not personalized investment advice.
